Long-term health outcomes of chronic hepatitis C patients: A review of findings from REVEAL-HCV cohort study

BioMedicine (Netherlands)

Volumn 2, Issue 3, 2012, Pages 99-107

  Lee, Mei Hsuan ^a,b   Yang, Hwai I ^a,c,d   Chen, Chien Jen ^a,c,e   Hsieh, C Y ^f   Lee, H S ^f   Yang, P M ^f   Chen, C H ^f   Chen, J D ^f   Huang, S P ^f   Jan, C F ^e   Chen, T H H ^g   Sun, C A ^h   Wu, M H ⁱ   Chen, S Y ^j   Chu, K E ^k   Ho, S C ^l   Lu, T G ^l   Wu, W P ^m   Ou, T Y ^m   Lin, C G ⁿ   Shih, K C ^o   Chung, W S ^p   Li, C ^p   Chen, C C ^q   How, W C ^r   more..

^a GENOMICS RESEARCH CENTER   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^h TAIPEI CITY PSYCHIATRIC CENTER   (Taiwan)

ⁱ TZU CHI UNIVERSITY   (Taiwan)

^j SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^k Huhsi Health Center   (Taiwan)

^l Huhsi Health Center ^*

^m Department of Internal Medicine   (Taiwan)

ⁿ Provincial Chutung Hospital   (Taiwan)

^o Provincial Potzu Hospital   (Taiwan)

^p Kaohsu Health Center   (Taiwan)

^q Kaohsu Health Center   (Taiwan)

^r Paihsa Health Center   (Taiwan)

more..

Author keywords

Extrahepatic diseases; Hepatic diseases; Prospective study; Serum HCV RNA

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; VIRUS RNA;

AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CANCER INCIDENCE; CANCER RISK; CAUSE OF DEATH; DISEASE ASSOCIATION; GENOTYPE; HEPATITIS C; HUMAN; INFECTION RISK; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MORTALITY; OUTCOME ASSESSMENT; REVIEW; RISK ASSESSMENT; SEROPREVALENCE; SEX DIFFERENCE;

HEPATITIS C VIRUS;

EID: 84866499776     PISSN: 22118020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomed.2012.06.002     Document Type: Review

References (50)

1. Lauer G.M., Walker B.D. Hepatitis C virus infection [see comment]. N Engl J Med 2001, 345:41-52.
2. Fattovich G., Stroffolini T., Zagni I., Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004, 127:S35-S50.
3. Parkin D.M. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006, 118:3030-3044.
4. Lu S.N., Su W.W., Yang S.S., Chang T.T., Cheng K.S., Wu J.C., et al. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer 2006, 119:1946-1952.
5. Yeh S.H., Tsai C.Y., Kao J.H., Liu C.J., Kuo T.J., Lin M.W., et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 2004, 41:659-666.
6. Liu C.J., Chuang W.L., Lee C.M., Yu M.L., Lu S.N., Wu S.S., et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009, 136:496-504.
7. Lin D.Y., Sheen I.S., Chiu C.T., Lin S.M., Kuo Y.C., Liaw Y.F. Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study. J Clin Ultrasound 1993, 21:303-308.
8. Yu M.W., Hsu F.C., Sheen I.S., Chu C.M., Lin D.Y., Chen C.J., et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997, 145:1039-1047.
9. Iloeje U.H., Yang H.-I., Su J., Jen C.L., You S.L., Chen C.J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686.
10. Sun C.A., Chen H.C., Lu C.F., You S.L., Mau Y.C., Ho M.S., et al. Transmission of hepatitis C virus in Taiwan: prevalence and risk factors based on a nationwide survey. J Med Virol 1999, 59:290-296.
11. Sun C.A., Chen H.C., Lu S.N., Chen C.J., Lu C.F., You S.L., et al. Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic risk factors. J Med Virol 2001, 65:30-34.
12. Lee M.H., Yang H.I., Jen C.L., Lu S.N., Yeh S.H., Liu C.J., et al. Community and personal risk factors for hepatitis C virus infection: a survey of 23,820 residents in Taiwan in 1991-2. Gut 2011, 60:688-694.
13. Lee M.H., Yang H.I., Lu S.N., Jen C.L., Yeh S.H., Liu C.J., et al. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol 2010, 28:4587-4593.
14. Huang Y.T., Jen C.L., Yang H.I., Lee M.H., Su J., Lu S.N., et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol 2011, 29:3643-3650.
15. Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012, in press.
16. Lee M.H., Yang H.I., Wang C.H., Chen C.J. Response to letter by Lin et al regarding article, "Hepatitis C virus infection and increased risk of cerebrovascular disease" Stroke 2011, 42:e390-e391.
17. Lee M.H., Yang H.I., Wang C.H., Jen C.L., Yeh S.H., Liu C.J., et al. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke 2010, 41:2894-2900.
18. Hisada M., Chatterjee N., Kalaylioglu Z., Battjes R.J., Goedert J.J. Hepatitis C virus load and survival among injection drug users in the United States. Hepatology 2005, 42:1446-1452.
19. Wiese M., Berr F., Lafrenz M., Porst H., Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000, 32:91-96.
20. Wiese M., Grungreiff K., Guthoff W., Lafrenz M., Oesen U., Porst H., et al. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany-a 25-year multicenter study. J Hepatol 2005, 43:590-598.
21. Velosa J., Serejo F., Marinho R., Nunes J., Glória H. Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis. Dig Dis Sci 2011, 56:1853-1861.
22. Yoshida H., Shiratori Y., Moriyama M., Arakawa Y., Ide T., Sata M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999, 131:174-181.
23. Brown J.L. Interferon therapy reduces the risk for hepatocellular carcinoma. Gut 2000, 47:610-611.
24. Nishiguchi S., Kuroki T., Nakatani S., Morimoto H., Takeda T., Nakajima S., et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995, 346:1051-1055.
25. Yu M.L., Lin S.M., Chuang W.L., Dai C.Y., Wang J.H., Lu S.N., et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther 2006, 11:985-994.
26. Shiratori Y., Ito Y., Yokosuka O., Imazeki F., Nakata R., Tanaka N., et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005, 142:105-114.
27. Lok A.S., Gardiner D.F., Lawitz E., Martorell C., Everson G.T., Ghalib R., et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012, 366:216-224.
28. Zeuzem S., Andreone P., Pol S., Lawitz E., Diago M., Roberts S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
29. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Gen 2009, 41:1100-1104.
30. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41:1105-1109.
31. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
32. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
33. Hsu C.S., Hsu S.J., Chen H.C., Tseng T.C., Liu C.H., Niu W.F., et al. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc Natl Acad Sci USA 2011, 108:3719-3724.
34. Eurich D., Boas-Knoop S., Bahra M., Neuhaus R., Somasundaram R., Neuhaus P., et al. Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy. Transplantation 2012, 93:644-649.
35. Huang C.F., Huang J.F., Yang J.F., Hsieh M.Y., Lin Z.Y., Chen S.C., et al. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J Hepatol 2012, 56:34-40.
36. Lin C.Y., Chen J.Y., Lin T.N., Jeng W.J., Huang C.H., Huang C.W., et al. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One 2011, 6:e18322.
37. Yu M.L., Huang C.F., Huang J.F., Chang N.C., Yang J.F., Lin Z.Y., et al. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011, 53:7-13.
38. Liu C.H., Kao J.H. Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives. J Gastroenterol Hepatol 2011, 26:1348-1353.
39. Kumar V., Kato N., Urabe Y., Takahashi A., Muroyama R., Hosono N., et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet 2011, 43:455-458.
40. Miki D., Ochi H., Hayes C.N., Yoshima T., Aikata H., Ikeda K., et al. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet 2011, 43:797-800.
41. Abu Dayyeh B.K., Yang M., Fuchs B.C., Karl D.L., Yamada S., Sninsky J.J., et al. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 2011, 141:141-149.
42. Yu M.L., Lin S.M., Lee C.M., Dai C.Y., Chang W.Y., Chen S.C., et al. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology 2006, 44:1086-1097.
43. Lok A.S., Seeff L.B., Morgan T.R., di Bisceglie A.M., Sterling R.K., Curto T.M., et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009, 136:138-148.
44. Lee M.H., Yang H.I., Lu S.N., Jen C.L., You S.L., Wang L.Y., et al. Clinical scoring system for prediction of long-term risk for hepatocellular carcinoma among hepatitis C virus infected patients. Hepatology International 2012, 11. (abstract).
45. Ghany M.G., Lok A.S., Everhart J.E., Everson G.T., Lee W.M., Curto T.M., et al. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2010, 138:136-146.
46. Fontana R.J., Goodman Z.D., Dienstag J.L., Bonkovsky H.L., Naishadham D., Sterling R.K., et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008, 47:789-798.
47. Ghany M.G., Kim H.Y., Stoddard A., Wright E.C., Seeff L.B., Lok A.S., et al. Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology 2011, 54:1527-1537.
48. Yu M.L., Chuang W.L. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009, 24:336-345.
49. Liu C.H., Liu C.J., Lin C.L., Liang C.C., Hsu S.J., Yang S.S., et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008, 47:1260-1269.
50. Imazeki F., Yokosuka O., Fukai K., Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology 2003, 38:493-502.